Quality of life (QoL) outcomes with futibatinib treatment in FOENIX-CCA2-A phase II study in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 gene fusions/rearrangements

被引：0
|
作者：
Valle, J. W. [1 ]
Hollebecque, A. [2 ]
Furuse, J. [3 ]
Goyal, L. [4 ]
Meric-Bernstam, F. [5 ]
Morlock, R. [6 ]
He, Y. [7 ]
Benhadji, K. [8 ]
Bridgewater, J. [9 ]
机构：
[1] Univ Manchester, Div Canc Sci, Christie NHS Fdn Trust, Manchester, Lancs, England
[2] Gustave Roussy, DITEP Drug Dev Dept, Villejuif, France
[3] Kyorin Univ, Dept Med Oncol, Sch Med, Tokyo, Japan
[4] Massachusetts Gen Hosp, Dept Med Hematol Oncol, Boston, MA 02114 USA
[5] Univ Texas MD Anderson Canc Ctr, Invest Canc Therapeut, Houston, TX 77030 USA
[6] YourCareChoice, Sci Collaborator, Ann Arbor, AL USA
[7] Taiho Oncol, Biostat, Princeton, NJ USA
[8] Taiho Oncol Inc, Clin Dev Dept, Princeton, NJ USA
[9] UCL, Dept Med Oncol, Canc Inst, London, England
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.08.036
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
58P
引用
收藏
页码：S263 / S264
页数：2
相关论文
共 38 条
  • [31] Infigratinib versus gemcitabine plus cisplatin multicenter, open-label, randomized, phase 3 study in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: The PROOF trial.
    Javle, Milind M.
    Borbath, Ivan
    Clarke, Stephen John
    Hitre, Erika
    Louvet, Christophe
    Mercade, Teresa Macarulla
    Oh, Do-Youn
    Spratlin, Jennifer L.
    Valle, Juan W.
    Weiss, Karl Heinz
    Berman, Craig
    Howland, Michael
    Ye, Yining
    Cho, Terry
    Moran, Susan
    Abou-Alfa, Ghassan K.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [32] Phase 3 multicenter, open-label, randomized study of infigratinib versus gemcitabine plus cisplatin in the first-line treatment of patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF trial
    Javle, M.
    Borbath, I.
    Clarke, S.
    Hitre, E.
    Louver, C.
    Macarulla, T.
    Oh, D.
    Spratlin, J.
    Valee, J.
    Weiss, K.
    Berman, C.
    Howland, M.
    Ye, Y.
    Cho, T.
    Moran, S.
    Abou-Alfa, C.
    ANNALS OF ONCOLOGY, 2019, 30 : 62 - 62
  • [33] Phase I study evaluating KIN-3248, a next-generation, irreversible pan-FGFR inhibitor, in patients with advanced cholangiocarcinoma, urothelial carcinoma and other solid tumors harboring FGFR2 and/or FGFR3 gene alterations
    Garmezy, B.
    Borad, M.
    Lin, C. C.
    Chen, L. T.
    Perez, C. A.
    Kato, S.
    Tam, B.
    Severson, P.
    Quah, C. S.
    Harding, J. J.
    ANNALS OF ONCOLOGY, 2023, 34 : S231 - S232
  • [34] Final results from the phase 2, open-label FOENIX-MBC2 study: efficacy and safety of futibatinib in adult patients with locally advanced/metastatic HR+/HER2-breast cancer harboring high-level FGFR1 gene amplification
    Damodaran, Senthil
    Andre, Fabrice
    Unni, Nisha
    Ferreira, Marta
    Giridhar, Karthik
    Daniel, Brooke
    Colleoni, Marco
    Costa, Luis
    Bachelot, Thomas
    O'Brien, Ciara
    Wright, Gail
    Shimura, Masashi
    Tomlinson, Gareth
    Gil, Maciej
    Turner, Nicholas
    CANCER RESEARCH, 2024, 84 (09)
  • [35] Quality of life (QoL) outcomes in patients (pts) with zanidatamab (zani)-treated HER2-positive (HER2+) biliary tract cancer (BTC) in the phase IIb HERIZON-BTC-01 study
    Wasan, H. S.
    Harding, J. J.
    Fan, J.
    Oh, D-Y.
    Choi, H. J.
    Kim, J. W.
    Chang, H-M.
    Bao, L.
    Sun, H.
    Macarulla, T.
    Xie, F.
    Metges, J-P.
    Ying, J.
    Bridgewater, J. A.
    Tejani, M.
    Chen, E. Y.
    Ducreux, M. P.
    Ma, J.
    Garfin, P.
    Pant, S.
    ANNALS OF ONCOLOGY, 2023, 34 : S219 - S219
  • [36] First in human (FIH) phase 1/1b study evaluating KIN-3248, a next-generation, irreversible pan-FGFR inhibitor (FGFRi), in patients (pts) with advanced urothelial carcinoma (UC) and other solid tumors harboring FGFR2 and/or FGFR3 gene alterations.
    Garmezy, Benjamin
    Perez, Cesar Augusto
    Kato, Shumei
    Sharma, Manish
    Quah, Cheng Seok
    Tam, Betty
    Severson, Paul
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [37] Longitudinal quality of life (QoL) study in a randomized phase II trial (FFCD 9803) assessing LV5FU2, LV5FU2-cisplatin or LV5FU2-irinotecan in patients (pts) with metastatic gastric adenocarcinoma (MGA)
    Bonnetain, F
    Bouche, O
    Raoul, JL
    Giovannini, M
    Etienne, PL
    Bedenne, L
    Seitz, JF
    Lledo, G
    Conroy, T
    Arveux, P
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 350S - 350S
  • [38] Improved Quality of Life (QOL) with Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy, Compared with Standard of Care (SOC) As Second-Line (2L) Treatment in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 3 Transform Study
    Abramson, Jeremy S.
    Solomon, Scott R.
    Arnason, Jon E.
    Johnston, Patrick B.
    Glass, Bertram
    Crotta, Alessandro
    Montheard, Sandrine
    Previtali, Alessandro
    Liu, Fei Fei
    Braverman, Julia
    Guo, Shien
    Shi, Ling
    Kamdar, Manali
    BLOOD, 2021, 138 : 3845 - +
1234